MOLECULAR INFORMATION
Molecular information
- Type
- Cathelicidin-derived antimicrobial peptide · 37 residues · broad-spectrum
LL-37 is the active cathelicidin antimicrobial peptide of human innate immunity, also developed as an investigational therapeutic.
Status
- Phase 2 in chronic wound healing (e.g. venous leg ulcers, diabetic foot ulcers)
- Preclinical work in respiratory infections, biofilm disruption
- No Phase 3, no marketing authorisation
Why we grade it C
Real endogenous human peptide with extensive mechanistic and preclinical literature, plus active clinical-stage programmes. The upgrade from D requires a completed adequately-powered Phase 3 in some indication.
Frequently asked questions
- What is LL-37?
- A 37-amino-acid antimicrobial peptide derived from the human cathelicidin precursor hCAP18. Endogenous component of innate immunity; under clinical investigation as a topical wound-healing and infection-control therapeutic.
- Is LL-37 authorised?
- No — no marketing authorisation in any major jurisdiction. Several Phase 1/2 trials in chronic wounds and infections; no Phase 3.
- Why grade C?
- Genuine human peptide with broad mechanistic support and active clinical programmes — distinct from purely grey-market peptides. But no completed pivotal trial, so the therapeutic claims aren't yet supportable.